Lars Fruergaard Jørgensen

Lars Fruergaard Jørgensen began his career at Novo Nordisk as an economist in the health care, economy, and planning department more than 30 years ago. He has served as CEO since 2017, and overseen recent blockbuster growth at the company thanks to Ozempic and Wegovy, two drugs with widespread use as weight-loss medications. Overall sales increased by more than 30% in 2023 alone, but the Danish-based company faces increased competition this year as well as supply challenges.